<DOC>
	<DOC>NCT01023971</DOC>
	<brief_summary>The purpose of this study is to determine the changes in macular function during anti-VEGF treatment for neovascular age-related macular degeneration.</brief_summary>
	<brief_title>Macular Function During Anti-VEGF Treatment</brief_title>
	<detailed_description>Macular function will be investigated using visual acuity, contrast sensitivity, mfERG and microperimetry.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Neovascular AMD in first or second eyes angiographic signs of active subfoveal or juxtafoveal choroidal neovascularization (CNV) BCVA ≥35 ETDRS letters Spherical equivalent ≥ ± 6 D Previous treatments for CNV in the studied eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>